Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Fabry Disease

• Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease
• Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease
• A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
• Switch Over Study of Biosimilar AGA for Fabry Disease
• Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease
• Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients
• A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
• A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Adult Participants With Fabry Disease
• China Post-marketing Surveillance (PMS) Study of Fabrazyme®
• A Study of Replagal in Treatment-naïve Adults With Fabry Disease
• Effect of Cannabinoids on Pain in Fabry Disease Patients
• To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease
• Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease
• A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variants and Severe Renal Impairment
• A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease
• Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients
• Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease
• Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)
• FAB- GT Open-Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment -Naive Subjects With Classic Fabry Disease
• Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease
• Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease
• Pharmacokinetics, Pharmacodynamics, and Safety of Moss-aGalactosidase A in Patients With Fabry Disease
• Fabry: Renal Function During Long-term ERT by 51Cr-EDTA Clearance
• Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry Disease
• A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease
• Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease
• Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease
• Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease
• Paricalcitol in Fabry Disease
• A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers
• Clinical Investigation on the Blood Oxygenation at the Optic Nerve Head in Fabry Patients
• Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients.
• Extension Study of PRX-102 for 24 Months
• A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects
• A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
• Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
• A Study to Assess the Absorption, Metabolism and Excretion of Migalastat Hydrochloride (AT1001-014)
• Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
• Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
• Evaluate the Safety and Exploratory Efficacy of GC1119
• Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease
• Migalastat Food Effect Study
• Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease
• Open-Label Phase 3 Long-Term Safety Study of Migalastat
• Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
• Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease
• Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease
• Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study
• Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease
• Canadian Fabry Disease Initiative (CFDI) Enzyme Replacement Therapy (ERT) Study
• The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study
• An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease
• A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency.
• A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease
• A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease
• A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease
• A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease.
• A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease
• A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease
• Replagal Enzyme Replacement Therapy for Adults With Fabry Disease
• Replagal Enzyme Replacement Therapy for Children With Fabry Disease
• Alternative Dosing and Regimen of Replagal to Treat Fabry Disease
• A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease
• An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease
• Dosing Study of Replagal in Patients With Fabry Disease
• Alpha-Galactosidase A Replacement Therapy for Fabry Disease